REMOOD

Generic

Flupentixol + Melitracen

Indications

Remood is indicated in various types of anxiety, depression and apathy. These include-

• Psychogenicdepression
• Depressive neurosis
• Masked depression
• Psychosomatic affections accompanied by anxiety and apathy E Menopausaldepressions
• Dysphoria and depression in alcoholics and drug-addicts

Pharmacology

This is made up of two well-known and well-proven compounds: flupentixol, a neuroleptic with anxiolytic and antidepressant characteristics at modest dosages, and melitracen, a bipolar thymoleptic with activating qualities in low doses. When the chemicals are combined, they produce a formulation having depressive, anxiolytic, and activating effects. The maximum blood concentration of flupentixol is achieved about 4 hours after oral administration, while the maximum serum concentration of melitracen is reached around 4 hours after oral administration. Flupentixol has a biological half-life of approximately 35 hours while melitracen has a biological half-life of approximately 19 hours. The combination of flupentixol and melitracen does not appear to affect the separate drugs' pharmacokinetic characteristics.

Dosage & Administration

Adults: Usually 2 tablets daily: morning and noon. In severe cases the morning dose may be increasedto 2 tablets.

Elderly patients: l tablet in the morning. Maintenance dose: Usually l tablet in the morning. ln cases of insomnia or severe restlessness additional treatment with sedative in the acute phase is recommended. 

Interaction

Flupentixol-melitracen may enhance the response to alcohol, barbiturates and other CNS depressants. Simultaneous administration of MAO-inhibitors may cause hypertensive crisis. Neuroleptics and thymoleptics reduce the antihypertensive effect of guanethidine and similar acting compounds and thymoleptics enhance the effects of adrenaline and noradrenaline.

Contraindications

The immediate recovery phase after myocardial infarction. Defects in bundle-branch conduction. untreated narrow angle glaucoma. Acute alcohol, barbiturate and opiate intoxications. Flupentixol-melitracen should not be given to patients who have received a MAo-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.

Side Effects

ln the recommended doses side-effects are rare. These could be transient restlessness and insomnia.

Pregnancy & Lactation

Flupentixol-melitracen should preferably not be given during pregnancy and lactation.

Precautions & Warnings

lf previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.

Therapeutic Class

Anxiolytics and antidepressants used together.

Storage Conditions

Store in a dry location at a temperature not exceeding 30°C. Keep out of direct sunlight. Keep out of children's reach.

Pharmaceutical Name

Ibn Sina Pharmaceuticals Ltd.